Implementing less invasive surfactant administration on a neonatal unit

Arch Dis Child Educ Pract Ed. 2022 Aug;107(4):298-301. doi: 10.1136/archdischild-2020-320574. Epub 2021 Apr 8.

Abstract

There is increasing evidence reflected in both UK 2019 NICE and European guidelines suggesting that less invasive surfactant administration (LISA) reduces the need for mechanical ventilation and reduces the combined outcome of death or bronchopulmonary dysplasia, and is now the optimal method for surfactant delivery in spontaneously breathing babies. Despite this, uptake in England has been slow compared with Europe. This quality improvement project outlines the process of implementing LISA in a neonatal intensive care unit over a 2-year period, the barriers and challenges which were encountered, and how they were overcome.

Keywords: data collection; neonatology.

MeSH terms

  • Bronchopulmonary Dysplasia* / drug therapy
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Pulmonary Surfactants* / therapeutic use
  • Respiratory Distress Syndrome, Newborn* / drug therapy
  • Surface-Active Agents / therapeutic use

Substances

  • Pulmonary Surfactants
  • Surface-Active Agents